What is LTZ Therapeutics?
Founded in 2022 and based in Redwood City, California, LTZ Therapeutics is dedicated to pioneering immunotherapies designed to overcome resistance and enhance anti-tumor immunity. Leveraging reverse translational science and a deep understanding of the tumor microenvironment, the company aims to improve clinical outcomes for patients battling cancer and other serious conditions. LTZ Therapeutics is positioned at the forefront of biotech innovation, seeking to translate cutting-edge biological insights into life-changing treatments.
How much funding has LTZ Therapeutics raised?
LTZ Therapeutics has raised a total of $102M across 2 funding rounds:
Other Financing Round
$27M
Series A
$20M
Other Financing Round (2023): $27M with participation from K-2 Venture Partners, Qiming Venture Partners, Qiming Venture Partners, and Tigermed
Series A (2024): $20M led by Shunwei Capital, GL Ventures, and K2 Venture Partners
Key Investors in LTZ Therapeutics
Shunwei Capital
Shunwei Capital is a venture capital firm specializing in technology-driven industries, focusing on startups and growth-stage companies, particularly in the IoT sector.
GL Ventures
GL Ventures, LLC is a consulting firm that collaborates with entrepreneurs and CEOs to develop growth strategies for under-capitalized and emerging companies, also providing investment opportunities.
K2 Venture Partners
K2 Venture Partners is a software development studio focused on zero-to-one product development and fractional CTO/CPO services for ambitious companies across various industries.
What's next for LTZ Therapeutics?
The substantial capital infusion, particularly the recent strategic investment, signals a pivotal growth phase for LTZ Therapeutics. This backing is anticipated to fuel critical research and development initiatives, potentially enabling the company to advance its lead candidates through clinical trials and expand its therapeutic portfolio. The company's focus on overcoming immunotherapy resistance suggests a strategic direction towards tackling complex oncological challenges, positioning LTZ Therapeutics for significant advancements in the competitive biotech landscape.
See full LTZ Therapeutics company page
